@biofinder.bsky.social
đ€ 47
đ„ 5
đ 124
New BioFINDER preprint! We formalise the AÎČâtauâneurodegeneration (ATN) framework into a mechanism-based model of Alzheimerâs disease, enabling us to simulate longitudinal imaging biomarkers and study how disease processes evolve and interact across the AD continuum.
www.biorxiv.org/content/10.6...
loading . . .
25 days ago
1
4
1
New paper out in EMBO Mol Med! We use machine learning to predict AÎČ-PET burden from fluid biomarkers.
www.embopress.org/doi/full/10....
Key findings: - Performance RÂČâ=â0.79 - CSF AÎČ42/AÎČ40 most predictive of AÎČ plaque presence - Plasma p-tau217 best for tracking increasing amyloid plaque burden
loading . . .
Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and ÎČ-amyloid | EMBO Molecular Medicine
imageimageMachine-learning models using CSF and plasma biomarkers accurately predicted quantitative AÎČ-PET burden. Distinct contributions of soluble AÎČ42/AÎČ40 and plasma P-tau217 reveal their role in ...
https://www.embopress.org/doi/full/10.1038/s44321-025-00348-7
3 months ago
1
2
2
đšPaper Out! Systematic Review & Meta-analysis of ALS Fluid Biomarkers đ§”Key findings: âą NfL leads for both diagnosis (AUC 0.81â0.92) & prognosis (HR 2.8â4.3) âą CSF chitinases, p-tau/t-tau: moderate values âą Marked heterogeneity
onlinelibrary.wiley.com/doi/10.1111/...
loading . . .
https://onlinelibrary.wiley.com/doi/10.1111/ene.70382
4 months ago
1
0
1
đšNew publication in Alzheimer's & Dementia! In this perspective paper, we discuss whether AÎČ blood biomarkers can replace the accepted reference standard, AÎČ-PET, for assessing AÎČ burden. đFull paper:
alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
loading . . .
Complementary utility of plasma biomarkers and AÎČâPET for diagnosis, riskâstratification, and treatment monitoring in Alzheimer's disease
With the rapid development of blood biomarkers (BBMs) related to amyloid-ÎČ (AÎČ) pathology in Alzheimer's disease (AD), the question arises whether these can replace the accepted reference standard, ...
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70763
4 months ago
1
1
0
đšNew publication in Brain Communications! In this study led by Atul Kumar, we show that microglial cells play a key role in Alzheimer's disease, particularly in regulating changes in soluble tau, based on cell-type-specific genetic evidence. đFull paper:
academic.oup.com/braincomms/a...
loading . . .
Cell-weighted polygenic risk scores are associated with ÎČ-amyloid and tau biomarkers in Alzheimerâs disease
Kumar et al. report distinct cellular effects on measures of ÎČ-amyloid and tau. Importantly, they also found cell-level genetic evidence for a role for mic
https://academic.oup.com/braincomms/article/7/5/fcaf353/8252809
5 months ago
0
1
0
đšPaper alertđš New publication in JAMA Neurology led by
@gsalvado.bsky.social
. In a multicentric study, we examined the clinical utility to assess preclinical
#Alzheimerâs
disease in cognitively unimpaired individuals.
jamanetwork.com/journals/jam...
A đ§”...
loading . . .
Plasma P-Tau217 to Identify Preclinical AD
This cohort study evaluates the use of plasma phosphorylated tau 217 in identifying preclinical Alzheimer disease in individuals with amyloid ÎČ pathology.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2838887
6 months ago
1
2
2
đšNew publication in Nature Medicine! In this study, we demonstrate that a brief, self-administered cognitive test battery can reliably identify individuals with cognitive impairment in a primary care setting. More details:
linkedin.com/feed/update/...
Full paper:
www.nature.com/articles/s41...
loading . . .
Primary care detection of Alzheimerâs disease using a self-administered digital cognitive test and blood biomarkers - Nature Medicine | The Swedish BioFINDER study
New publication in Nature Medicine!  In this study, led by PhD students Pontus Tideman and Linda Karlsson, we demonstrate that a brief, self-administered cognitive test battery can reliably identify ...
https://linkedin.com/feed/update/urn:li:activity:7373343626438979584
6 months ago
1
2
1
đšNew paper alert! Our study led by
@teanijarv.bsky.social
investigated why some individuals with Alzheimerâs disease (AD) develop hemispheric asymmetry in tau pathology and what drives this phenomenon. Out now in Nature Communications! đFull article:
doi.org/10.1038/s414...
A threadđ§”đ
loading . . .
Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimerâs Disease - Nature Communications
Asymmetrical distribution of tau pathology in Alzheimerâs disease is linked to asymmetrical amyloid-beta deposition, not reduced brain connectivity, suggesting regional vulnerability plays a key role ...
https://doi.org/10.1038/s41467-025-63564-2
6 months ago
1
6
4
đšNew publication in Nature Agingđš Co-led between Laia Montoliu-Gaya and
@gsalvado.bsky.social
. We measured several tau peptides in blood and assess their different relationships with Alzheimerâs disease stages.
nature.com/articles/s43...
đ§”
loading . . .
Plasma tau biomarkers for biological staging of Alzheimerâs disease - Nature Aging
Montoliu-Gaya, SalvadĂł et al. develop a blood-based model using tau biomarkers measured in a single analysis enabling biological staging of Alzheimerâs disease to support the diagnosis, prognosis and ...
https://nature.com/articles/s43587-025-00951-w
7 months ago
1
0
1
đšNew paper alert! This study led by Sophie Mastenbroek aims to make detection of α-synuclein pathology in the brain more time- and cost-effective. Out now in Nature Communications! đ Full article:
nature.com/articles/s41...
A threadđ§”đ
loading . . .
Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification
Nature Communications - CSF α-synuclein seed amplification assays detect Lewy body pathology accurately but are invasive and costly. Here, the authors show that a two-step workflow using...
https://nature.com/articles/s41467-025-62458-7.epdf?sharing_token=fJsM7nw6WLFQSLEmJtlXiNRgN0jAjWel9jnR3ZoTv0MDVkWnZxGsgtCMfY18v2PG-JBJvKhRsSwlFHbyWcVEhi_UdJDYtyqFZKb0-1LE-RJuxLzTxso4Wsn_ZLSgyRQKvtbjLPDfKEVHUrWMYnYD648e1kcTBiQcj_tBKohdF6g%3D
7 months ago
1
1
0
đšThis study led by
@anikawuestefeld.bsky.social
aims to provide a more granular understanding of how tau pathology leads to specific cognitive decline in Alzheimer's disease. đ§ Out now in Alzheimerâs & Dementia! Read it here:
doi.org/10.1002/alz....
đ§”đ
loading . . .
Tau, atrophy, and domainâspecific cognitive impairment in typical Alzheimer's disease
INTRODUCTION A granular understanding of the mechanisms linking tau pathology to cognitive decline in Alzheimer's disease is crucial. We investigate mediating effects of medial temporal lobe (MTL) a...
https://doi.org/10.1002/alz.70511
7 months ago
1
2
2
New manuscript alert! Are plasma biomarkersđ©ž predictive of Alzheimerâs disease progression in Down Syndrome (DS)? Our new study in collaboration with the ABC-DS consortium has now been published in
@thelancetneuro.bsky.social
:
www.thelancet.com/journals/lan...
loading . . .
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study
Baseline and longitudinal plasma p-tau217 were associated with subsequent decline in global cognition, progression to dementia, and increased tau burden, whereas baseline p-tau217 and GFAP were associ...
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00158-9/fulltext
8 months ago
1
2
2
đšExciting new preprint from a great collaboration between our group and the talented PhD student
@jorittmo.bsky.social
from
@jwvogel.bsky.social
's group! They investigate how the đ§ reorganises in the context of age and AD. Dive into the details here đ§”đ
add a skeleton here at some point
9 months ago
0
2
0
đšNew paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tauđhttps://pubmed.ncbi.nlm.nih.gov/40289884/
10 months ago
1
2
2
đ§ Exciting new findings from a great collaboration between the BioFINDER study and the talented
@xiaoyucaly.bsky.social
from
@jwvogel.bsky.social
group!! In their preprint, they show that tau presence and tau load are guided by unique brain mechanisms. Dive into the details here đ
add a skeleton here at some point
11 months ago
0
2
3
âŒïžNew preprint! We are happy to share our latest work led by
@teanijarv.bsky.social
investigating why tau pathology in AD often accumulates more in one hemisphere of the brain than the other. Check out đhttps://biorxiv.org/content/10.1101/2025.04.15.648728v1 or dive into the details belowđ
11 months ago
1
4
5
đšNew paper alert! Research from our group and collaborators at The University of Melbourne shows increased speed of neuronal aging in schizophrenia- the same phenomena was not seen in bipolar disorder. đRead more here:
theconversation.com/brains-of-pe...
loading . . .
Brains of people with schizophrenia may age faster â how our research adds to the evidence
Study suggests accelerated brain ageing is a factor in the development of schizophrenia â and can be measured using a simple blood test.
https://theconversation.com/brains-of-people-with-schizophrenia-may-age-faster-how-our-research-adds-to-the-evidence-239979
11 months ago
0
0
0
New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimerâs disease (AD) pathology?đ©ž Our new multi-cohort study has now been published in
@naturemedicine.bsky.social
:
nature.com/articles/s41...
. A threadđ§”
loading . . .
Plasma phospho-tau217 for Alzheimerâs disease diagnosis in primary and secondary care using a fully automated platform - Nature Medicine
Among 1,767 patients in 5 centers, a fully automated blood test showed high accuracy for Alzheimerâs pathology in secondary and primary care using a predefined cutoff.
https://nature.com/articles/s41591-025-03622-w
11 months ago
1
4
4
A busy day today with many BioFINDER presentations and posters! Come find us at
#ADPD2025
!
11 months ago
0
0
0
Guten Morgen! đ Start the day with more presentations from our group.
11 months ago
0
0
0
We hope you had a great first day! Continuing
#ADPD2025
with a forum discussion on blood-based biomarkers by Oskar Hansson.
11 months ago
0
1
0
Donât miss out on our
#ADPD2025
on-demand presentations about brain reserve in frontotemporal dementia, a sensitive visual read algorithm for assessing tau PET images, and the correlation between biomarkers and and [18F] dopa-pet!
11 months ago
0
0
0
First day of
#ADPD2025
in Vienna! Come see our talks on plasma tau biomarkers đ©ž, in Hall A â 13:15-15:30.
11 months ago
0
0
0
If youâre joining đ§
#ADPD2025
in Vienna đŠđč this week, donât miss the BioFINDER posters and presentations! đ©ž Blood based biomarkers, đ§ tau PET, proteomics, and many other topics!
11 months ago
0
0
0
âŒïžNew publication on a novel plasma biomarker for tau pathology đ§ đ§Ș in
@naturemedicine.bsky.social
led by Kanta Horie &
@gsalvado.bsky.social
: đ
www.nature.com/articles/s41...
In this study, we investigated plasma eMTBR-tau243, which closely reflects tau tangle pathology in Alzheimerâs disease (AD).
loading . . .
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimerâs disease - Nature Medicine
Plasma eMTBR-tau243 is a specific biomarker of tau tangles in Alzheimerâs disease and enables the detecting and tracking of Alzheimerâs clinical impairment.
https://www.nature.com/articles/s41591-025-03617-7
11 months ago
1
3
3
đšNew publication led by
@rikossenkoppele.bsky.social
&
@gsalvado.bsky.social
at
@natureaging.bsky.social
:
www.nature.com/articles/s43...
We compared the role of plasma p-tau217 and tau-PET in predicting cognitive decline in cognitively unimpaired individuals and the implications for clinical trials.
loading . . .
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials - Nature Aging
Ossenkoppele, Salvado et al. show that plasma p-tau217 and tau-PET predict cognitive decline equally well among cognitively unimpaired individuals. Their combined use further boosts prognostic accurac...
https://www.nature.com/articles/s43587-025-00835-z
11 months ago
1
1
0
đšNew paper published in @alzdemjournals!
doi.org/10.1002/alz.14600
PhD student Linda Karlsson et al. use machine learning (ML) to predict tau-PET composites from accessible and inexpensive modalities: plasma biomarkers, structural MRI and clinical variables. Details đ
loading . . .
Machine learning prediction of tauâPET in Alzheimer's disease using plasma, MRI, and clinical data
INTRODUCTION Tau positron emission tomography (PET) is a reliable neuroimaging technique for assessing regional load of tau pathology in the brain, but its routine clinical use is limited by cost an...
https://doi.org/10.1002/alz.14600
about 1 year ago
1
2
1
A new The Swedish BioFINDER study paper in collaboration with WRAP has been published in Brain!
academic.oup.com/brain/advanc...
Find our key findings đ
loading . . .
APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta
Cicognola et al. investigate the relationship between the APOE4 geneâthe strongest genetic risk factor for Alzheimerâs diseaseâand tau. They find that the
https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awaf016/7958226?login=false
about 1 year ago
1
0
1
you reached the end!!
feeds!
log in
